By reducing the expression and activity of ATF3, CRLS1 reduces insulin resistance, hepatic steatosis, inflammation, and fibrosis during the pathological phase of non-alcoholic steatohepatitis (NASH) (10, 11). Here, ATF3 is linked to fatty liver disease.